Compare BNR & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNR | PDSB |
|---|---|---|
| Founded | 2014 | 2005 |
| Country | China | United States |
| Employees | N/A | 10 |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.5M | 42.4M |
| IPO Year | 2019 | 2015 |
| Metric | BNR | PDSB |
|---|---|---|
| Price | $15.65 | $1.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.75 |
| AVG Volume (30 Days) | 59.8K | ★ 50.3M |
| Earning Date | 11-19-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $101.46 | N/A |
| Revenue Next Year | $14.81 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.79 | $0.20 |
| 52 Week High | $41.72 | $1.55 |
| Indicator | BNR | PDSB |
|---|---|---|
| Relative Strength Index (RSI) | 57.61 | 78.42 |
| Support Level | $15.61 | $0.58 |
| Resistance Level | $19.10 | $1.32 |
| Average True Range (ATR) | 1.76 | 0.15 |
| MACD | 0.07 | 0.03 |
| Stochastic Oscillator | 57.76 | 86.66 |
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.